NLS Pharmaceutics Announces Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
Clinical Trial
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to...
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
CAMBRIDGE, MA / ACCESSWIRE / June 28, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA)...
Eyenovia Announces Pricing of $5M Registered Direct Offering
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company,...
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm...
CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s...
Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show...
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in...
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the...
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000...
cbdMD Announces Publication of Human Clinical Trial Data
Charlotte, North Carolina--(Newsfile Corp. - June 27, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the "Company"), one...
IoT in Healthcare Market: Digitization Surge to Propel Valuation Beyond $926.9B by 2031 | SkyQuest Technology
WESTFORD, Mass., June 27, 2024 /PRNewswire/ -- According to SkyQuest, the global IoT in Healthcare Market size was valued at USD...
Lindus Health Launches Bespoke “All-in-One Medical Device CRO” Offering for Medical Device Clinical Trials
NEW YORK, June 27, 2024 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life...
RareCyte secures $20M financing to expand the Orion™ Spatial Biology platform including Multiplex Assay Reagents, Software and Precision Biology Services
SEATTLE, June 27, 2024 /PRNewswire/ -- RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company providing advanced Precision Biology...
The Caris Precision Oncology Alliance Welcomes Leading Cancer Center
Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine by...
Genflow Biosciences Plc Announces Result of AGM
LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging...
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson’s Disease Treatments
ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
TORONTO, ON / ACCESSWIRE / June 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to...
Zomedica Expands TRUFORMA Addressable Market with Launch of Equine Cortisol Assay for the Platform
First-of-its-kind stall-side testing to enable rapid, life-saving decisions for equine veterinarians ANN ARBOR, MI / ACCESSWIRE / June 27, 2024...
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficitsBETHESDA, Md.,...